Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Montelukast Sodium Market
Montelukast Sodium Market size was valued at around USD 670.7 million in 2023 and is estimated to grow at 11.4% CAGR from 2024 to 2032. Montelukast sodium is a medication primarily used for the treatment of asthma and allergic rhinitis. It belongs to a class of drugs known as leukotriene receptor antagonists, work by blocking the action of leukotrienes, substances in the body that contribute to inflammation, bronchoconstriction and other symptoms associated with asthma and allergies.
The increasing prevalence of respiratory diseases includes asthma, allergic rhinitis serves as a substantial impetus for market growth. For instance, according to the World Health Organization (WHO), in 2019, asthma impacted approximately 262 million individuals worldwide and also led to 455,000 deaths during the same period. Thus, this underscores the need for effective pharmaceutical interventions such as montelukast sodium, plays a crucial role in managing conditions such as asthma and allergic rhinitis, thereby alleviating symptoms, improving quality of life, and potentially reducing mortality rates associated with these respiratory diseases. Furthermore, advancements in drug delivery and growing awareness and diagnosis are the promoting factors fostering the growth of the market.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Montelukast Sodium Market Size in 2023: | USD 670.7 Million |
Forecast Period: | 2024 – 2032 |
Forecast Period 2024 – 2032 CAGR: | 11.4% |
2024 – 2032 Value Projection: | USD 1.7 Billion |
Historical Data for: | 2021 – 2023 |
No. of Pages: | 190 |
Tables, Charts & Figures: | 273 |
Segments covered: | Product Type, Dosage Form, Application, Distribution Channel, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|